Loxo Loses Out Despite Signing Big Cancer Deal

Loxo Oncology has announced that it will be partnering with Bayer to develop and commercialize larotrectinib and LOXO-195. Investors seem to believe that Loxo would have been better on its own. At........»»

Category: blogSource: 247wallstNov 14th, 2017

A drugmaker that"s taking an unconventional approach to cancer drugs just got a $1.5 billion endorsement

Elaine Thompson/AP Bayer signed a partnership with cancer drugmaker Loxo Oncology in a deal that could be worth up to $1.5 billion.  Loxo is developing treatments that act on cancerous genet.....»»

Category: topSource: businessinsiderNov 14th, 2017

Loxo, Bayer to co-develop cancer drugs in up to $1.55 billion deal

Loxo Oncology Inc will collaborate with Germany's Bayer AG to develop and commercialize two of its cancer therapies......»»

Category: topSource: foxnewsNov 14th, 2017

Inova Health System inks $60 million proton therapy deal

Inova Health System plans to begin offering proton beam therapy at its Inova Schar Cancer Institute by 2020 after signing a $60 million contract for a proton system from Reston-based Ion Beam Applications S.A. The deal comes after Inova received r.....»»

Category: topSource: bizjournalsJul 7th, 2017

Loxo Is Being Unfairly Punished for a Big Licensing Deal: Gadfly

Loxo Is Being Unfairly Punished for a Big Licensing Deal: Gadfly.....»»

Category: topSource: washpostNov 14th, 2017

Loxo announces $400 mln Bayer cancer partnership

Loxo Oncology Inc. shares rose as much as 8% before declining nearly 3% in premarket trade on Tuesday after the com.....»»

Category: topSource: marketwatchNov 14th, 2017

Uber-SoftBank deal is said to be near approval, signing imminent

A multibillion-dollar deal that will see SoftBank Group Corp. take a big stake in Uber Technologies Inc. is close to being approved by the main players, people familiar with the matter said......»»

Category: topSource: moneycentralNov 12th, 2017

Iconix"s stock loses half its value after Walmart to end license deal and risk of debt covenant violations

Shares of Iconix Brand Group Inc. plunged 50% toward a 13-year closing low in afternoon trade Monday, after the .....»»

Category: topSource: marketwatchOct 30th, 2017

Novartis to Pay $3.9 Billion for Radio-Pharmaceuticals Firm

Novartis said it has agreed to acquire Advanced Accelerator Applications for $3.9 billion, a deal that would boost its oncology portfolio as generic competition eats into sales of blockbuster blood-cancer drug Gleevec......»»

Category: smallbizSource: wsjOct 30th, 2017

Novartis Looks to Buy French Firm to Bolster Cancer Portfolio

The $3.9 billion acquisition of Advanced Accelerator Applications would mark a rare deal in the pharmaceutical sector this year......»»

Category: dealsSource: nytOct 30th, 2017

Indian Oil aims 13.5 mn tonnes of LNG import capacity in 5 years

The company is also looking at signing a long-term LNG supply deal.....»»

Category: topSource: business-standardOct 27th, 2017

OmniSeq raises $10 million, inks deal with major national distributor

The Roswell Park Cancer Institute spin-off has about 50 employees at Hauptman-Woodward Medical Research Institute......»»

Category: topSource: bizjournalsOct 23rd, 2017

Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics

AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer. AbbVie Inc. ABBV announced that.....»»

Category: worldSource: nytOct 20th, 2017

Gilead: Congratulations…But You Still Overpaid for Kite

Gilead Sciences received FDA approval for a new cancer drug, a sign to some that its $12 billion acquisition of Kite Pharma is paying dividends. Yet Leerink analyst Geoffrey Porges still says Gilead overpaid  for the deal......»»

Category: blogSource: barronsOct 19th, 2017

Will Eli Lilly’s mRNA Cancer Vaccine Investment Hit Paydirt?

With Eli Lilly making a huge headline investment in a cancer vaccine, 24/7 Wall St. wanted to look under the hood to see what this deal really entails......»»

Category: blogSource: 247wallstOct 18th, 2017

How to Get a Deal With Every Investor on "Shark Tank," According to Daymond John

In an interview at the Inc. 5000 conference, the entrepreneur and investor dished on his TV show, his recent cancer scare, and his philosophy of success......»»

Category: topSource: incOct 13th, 2017

Eli Lilly Loses Some Luster

Eli Lilly's shares are getting hit by the combined pressure from an analyst downgrade and disappointing clinical trial results for a new cancer drug. .....»»

Category: blogSource: barronsOct 10th, 2017

Warriors owner reportedly had to be talked out of offering Stephen Curry a below-market contract after years of being the NBA"s most underpaid star

Stephen Curry cashed in this offseason by signing a five-year, $201 million deal, the biggest in NBA history .....»»

Category: topSource: businessinsiderOct 5th, 2017

Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up


Category: topSource: redinewsOct 4th, 2017

Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up

Endocyte (ECYT) acquired an exclusive worldwide license to develop and commercialize ABX GmbH's phase III-ready prostate cancer candidate 177Lu-PSMA-617. Shares of Endocyte, Inc. E.....»»

Category: worldSource: nytOct 3rd, 2017

Endocyte"s stock rockets again on heavy volume after license deal for prostate cancer treatment

Shares if Endocyte Inc. rocketed 49% on heavy volume Tuesday, an.....»»

Category: topSource: marketwatchOct 3rd, 2017